Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CKS1B | P61024 | 1/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | CCR6 | P51684 | 1/20 | 0.42 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8337316 | 0.82 | CYP4A11 (0.60) | CYP4A11CYP4F2LOXL2HPGDALDH1A1 | |
| SCHEMBL19922867 | 0.81 | CYP4A11 (0.64) | CYP4A11CYP4F2LOXL2HPGDALDH1A1 | |
| SCHEMBL316846 | 0.78 | MLYCD (0.52) | HPGDALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL7154419 | 0.77 | TAAR1 (0.46) | MAPTMEN1KMT2A | |
| SCHEMBL19002551 | 0.77 | CYP4A11 (0.62) | CYP4A11CYP4F2LOXL2HPGDALDH1A1 | |
| SCHEMBL880015 | 0.76 | CYP4A11 (0.66) | CYP4A11CYP4F2LOXL2HPGDALDH1A1 | |
| SCHEMBL70185 | 0.76 | CYP4A11 (0.75) | CYP4A11CYP4F2LOXL2HPGDALDH1A1 | |
| SCHEMBL19922221 | 0.75 | CYP4A11 (0.60) | CYP4A11CYP4F2LOXL2HPGDALDH1A1 | |
| SCHEMBL3426890 | 0.75 | CA2 (0.35) | CA1CA2 | |
| SCHEMBL12727813 | 0.75 | CYP1A2 (0.41) | ALDH1A1CYP1A2ALOX15MAPTCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087634-A1 | Fluorous Oligonucleotide Reagents and Affinity Purification of Oligonucleotides | BERRY & ASSOCIATES, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| EP-1831238-A2 | FLUOROUS OLIGONUCLEOTIDE REAGENTS AND AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | Berry & Associates , Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20060178507-A1 | Fluorous oligonucleotide reagents and affinity purification of oligonucleotides | BERRY & ASSOCIATES, INC. | 2006-08-10 | — | — | US | disclosed |
| WO-2006081035-A2 | FLUOROUS OLIGONUCLEOTIDE REAGENTS AND AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | BERRY & ASSOCIATES, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178507-A1 | Fluorous oligonucleotide reagents and affinity purification of oligonucleotides | DCLRE1B, POLM, FBL | CYP4A11 4662/4885CYP4F2 2181/4885LOXL2 2206/4885 |
| US-20100087634-A1 | Fluorous Oligonucleotide Reagents and Affinity Purification of Oligonucleotides | DCLRE1B, POLM, FBL | CYP4A11 4662/4885CYP4F2 2181/4885LOXL2 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.